Bailard’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Bailard’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$1K	–	627
2019 Q1	$1K	Hold	500	–	–	﹤0.01%	539
2018 Q4	$1K	Hold	500	–	–	﹤0.01%	488
2018 Q3	$2K	Hold	500	–	–	﹤0.01%	526
2018 Q2	$2K	Hold	500	–	–	﹤0.01%	510
2018 Q1	$4K	Hold	500	–	–	﹤0.01%	475
2017 Q4	$4K	Hold	500	–	–	﹤0.01%	429
2017 Q3	$4K	Hold	500	–	–	﹤0.01%	300
2017 Q2	$5K	Hold	500	–	–	﹤0.01%	275
2017 Q1	$6K	Hold	500	–	–	﹤0.01%	292
2016 Q4	$6K	Hold	500	–	–	﹤0.01%	301
2016 Q3	$9K	Hold	500	–	–	﹤0.01%	315
2016 Q2	$5K	Hold	500	–	–	﹤0.01%	297
2016 Q1	$9K	Buy	+500	New	+$9.62K	﹤0.01%	250
2015 Q4	–	Sell	-500	Closed	-$23K	–	390
2015 Q3	$23K	Hold	500	–	–	﹤0.01%	246
2015 Q2	$16K	Hold	500	–	–	﹤0.01%	240
2015 Q1	$16K	Hold	500	–	–	﹤0.01%	234
2014 Q4	$19K	Buy	+500	New	+$13.8K	﹤0.01%	232

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bailard's NAVB Position: Q2 2019 in Review

Bailard sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 500 shares — an estimated $1K sold.

Bailard first reported a position in NAVB in Q4 2014 and held it in 17 quarters. The position peaked at $23K in Q3 2015. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

Bailard reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Bailard sold 500 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $1K.
Bailard first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2014 and held it in 17 quarters.
Bailard's Navidea Biopharmaceuticals Inc. position peaked at $23K in Q3 2015.
27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Bailard's 13F filing for Q2 2019, filed 26 Jul 2019.